Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of SYHA1813 versus investigator's choice therapy in recurrent or progressive high-grade meningioma not suitable for local treatment
CTR20261870Phase 3Active
- Sponsor
- Runshi Pharma
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of SYHA1813 in meningioma, sponsored by Runshi Pharma. Started May 2026; status: active.
02
Drugs
SYHA1813
03
Conditions
meningioma
Beyond the preview
Go deeper on CTR20261870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261870.